Phase II open label study of PTK787/ZK222584 [vatalanib] in adults patients with refractory or relapsed diffuse large cell lymphoma.

Trial Profile

Phase II open label study of PTK787/ZK222584 [vatalanib] in adults patients with refractory or relapsed diffuse large cell lymphoma.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2014

At a glance

  • Drugs Vatalanib (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2012 Planned end date changed from 1 Nov 2011 to 1 Nov 2012 as reported by ClinicalTrials.gov.
    • 17 Aug 2011 Planned end date changed from 1 Nov 2010 to 1 Nov 2011 as reported by ClinicalTrials.gov.
    • 15 Jan 2010 Planned end date changed from 1 Dec 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top